venBio Partners LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), venBio Partners LLC reported 5 stock positions worth $281.9 million. Its top holding was Alx Oncology (ALXO) at 38.4% of the portfolio, followed by Pharvaris (PHVS, 35.2%) and Harmony Biosciences (HRMY, 12.3%). Compared with Q4 2023, it sold out of 2 and reduced 2. The biggest sale was an exit from Rayzebio (RYZB).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001776382
- Portfolio Value
- $281.9M (Q1 2024)
- SEC Filing
- 0000905148-24-001442 ↗ filed May 15, 2024
Holdings Value
Holdings 5 stocks · $281.9M
| ALXO Alx Oncology Holdings Inc. | 38.37% | 9,699,925 | $108.2M | No change |
| PHVS Pharvaris NV | 35.17% | 4,289,304 | $99.1M | Reduce -12.8% |
| HRMY Harmony Biosciences Holdings | 12.33% | 1,035,396 | $34.8M | No change |
| SLRN Acelyrin Inc. | 9.23% | 3,852,470 | $26.0M | No change |
| ELEV Elevation Oncology Inc. | 4.91% | 2,696,133 | $13.8M | Reduce -7.5% |
Portfolio Sells Q4 2023 → Q1 2024
| RYZB Rayzebio Inc. | Sold out | 0.00% | −48.06 |
| IMPEL PHARMACEUTICALS INC | Sold out | 0.00% | −0.05 |
| ELEV Elevation Oncology Inc. | Reduce -7.5% | 4.91% | +4.67 |
| PHVS Pharvaris NV | Reduce -12.8% | 35.17% | +14.48 |
Portfolio Buys Q4 2023 → Q1 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 7 | $519.4M | PHVS, PBLS, ALMS, ACHV, ALXO |
| Q1 2026 | 6 | $280.6M | PHVS, ALMS, ALXO, HRMY, LYEL |
| Q4 2025 | 6 | $216.3M | PHVS, ALMS, HRMY, ALXO, LYEL |
| Q3 2025 | 6 | $176.4M | PHVS, ALMS, ALXO, HRMY, LYEL |
| Q2 2025 | 6 | $114.8M | PHVS, HRMY, ALMS, LYEL, ALXO |
| Q1 2025 | 7 | $123.6M | PHVS, ALMS, HRMY, SLRN, ALXO |
| Q4 2024 | 7 | $170.7M | PHVS, ALMS, HRMY, ALXO, ARTV |
| Q3 2024 | 6 | $194.3M | PHVS, ALMS, HRMY, ARTV, SLRN |
| Q2 2024 | 6 | $231.5M | PHVS, ALXO, ALMS, HRMY, SLRN |
| Q1 2024 | 5 | $281.9M | ALXO, PHVS, HRMY, SLRN, ELEV |